Analysis of clinical efficacy of irbesartan in the treatment of early renal damage of hypertension

Objective:To investigate the clinical efficacy of irbesartan in the treatment of early renal damage of hypertension.Methods:Eighty hypertensive patients with early renal damage were randomly divided into the amlodipine group and irbesartan group(40 cases each group).The amlodipine group and irbesartan group were treated with amlodipine and irbesartan,respectively.After 12 weeks of treatment,the blood pressure,renal function and vascular endothelial function were compared between two groups.Results:The systolic blood pressure,diastolic blood pressure and mean arterial pressure in two groups after treatment were significantly lower than before treatment(P<0.01),there was no statistical significance between two groups(P>0.05).The levels of 24 h UAER and β2-MG in irbesartan group were significantly lower than those in amlodipine group,the NO and vascular endothelial function in irbesartan group were significantly higher than those in amlodipine group,and the ET level in irbesartan group was significantly lower than that in amlodipine group(P<0.05 to P<0.01).The difference of the incidence rate of adverse reaction between two groups was not statistically significant(P>0.05).Conclusions:Irbesartan and amlodipine can effectively reduce the blood pressure in hypertension patients with early renal damage.The effect of irbesartan in improving renal and vascular endothelial function is better than that of amlodipine,and the use of irbesartan is worthy of attention.